

15th November 2018



PainChek Limited (**ASX: PCK**)
ABN 21 146 035 127
Suite 401, 35 Lime Street, Sydney, NSW, 2000
Registered Office: Suite 5, 95 Hay Street Subiaco WA 6008
www.painchek.com

RECEIPT OF R&D TAX INCENTIVE

The Company is please to advise it has received \$751,385 for its Research & Development Tax Incentive offset for the year ended 30 June 2018.


For further information contact:

Ian Hobson
Company Secretary
Tel: +61 8 9388 8290


Philip Daffas
Managing Director
Tel: +61 406-537-235

THE PAINCHEK® TECHNOLOGY:

PainChek® uses cameras in smartphones and tablets to capture a brief video of the person, which is analysed in real time using facial recognition software to detect the presence of facial micro-expressions that are indicative of the presence of pain.



PainChek® artificial intelligence assesses facial micro-expressions that are indicative of the presence of pain



PainChek® six domains of pain assessment that calculates pain severity score

This data is then combined with other indicators of pain, such as vocalisations, behaviours and movements captured to calculate a pain severity score. Due to its speed, ease of use and its reproducibility, PainChek® is a validated clinical tool used to detect and measure a person's pain, and then further measurements can be used to monitor the effectiveness of pain management.

PainChek® is being rolled out globally in two phases: first, PainChek® which is designed for adults who are unable to effectively verbalise their pain such as people with dementia, and second, PainChek® for Children who have not yet learnt to speak.